Prolonged infusion gemcitabine: A clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels

Investigational New Drugs

Volumn 15, Issue 2, 1997, Pages 115-121

  Pollera, Camillo F ^a   Ceribelli, Anna ^a   Crecco, Marcello ^b   Oliva, Cristina ^c   Calabresi, Federico ^d  

^a Ist Division of Medical Oncology   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c Eli Lilly Italia   (Italy)

^d Ist Regina Elena Stud Cura Tumori ^*

Author keywords

Gemcitabine; Low dose; Phase I study; Prolonged infusion; Solid tumors; Weekly schedule

Indexed keywords

GEMCITABINE; NUCLEOSIDE ANALOG;

ADULT; AGED; ALOPECIA; ANKLE EDEMA; ARTHRITIS; ARTICLE; BLADDER CANCER; BLEEDING; BLOOD TOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG INFUSION; FEMALE; FEVER; HEART MUSCLE ISCHEMIA; HUMAN; ILEUS; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; STOMACH CANCER; STROKE; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSION PUMPS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0030949235     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005817024382     Document Type: Article

References (12)

1. Lund B, Kristjansen PEG, Hansen HH: Clinical and preclinical activity of 2′ ,2′ -difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45-55, 1993
2. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarasoff P, Satterlee W, Raber MN and Plunkett W: A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 9:491-498, 1991
3. Pollera CF, Ceribelli A, Crecco M, Calabresi F: Weekly gemcitabine in advanced or metastatic solid tumors: A clinical phase I study. Invest New Drugs 12:111-119, 1994
4. Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarasoff P, Plunkett W: Pharmacologically directed design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 50:6823-6826, 1990
5. Grunewald R, Abbruzzese JL, Tarasoff P, Plunkett W: Saturation of 2′,2′-difluorodeoxycytidine 5′-tripphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine. Cancer Chemother Pharmacol 27:258-262, 1991
6. Grunewald R, Kantarjian H, Du M, Faucher K, Tarasoff P, Plunkett W: Gemcitabine in leukemia: A phase I clinical, plasma and cellular pharmacology study. J Clin Oncol 10:406-413, 1992
7. Ruiz van Haperen VWT, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ: Schedule dependence of sensitivity to 2′2′-difluorodeoxycytidine (gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumor cell lines and solid tumours. Biochem Pharmacol 48:1327-1231, 1994
8. Poplin E, Corbett T, Flaherty L, Tarasoff P, Redman BG, Valdivieso M, Baker L: Difluorodeoxycytidine (dFdC)-gemcitabine: A phase I study. Invest New Drugs 10:165-170, 1992
9. Anderson HH, Thatcher N, Walling J, Hansen H, Mejdal P: A phase I study of 24-hour infusion of Gemcitabine in patients with previously untreated locally advanced non-small cell lung cancer. B J Cancer 74:460-462, 1996
10. Miller AB, Hoogstraten B, Staquet B, Winkler A: Reporting results of cancer treatment. Cancer 47:207-224, 1981
11. Hryniuk WM, Goodyear M: The calculation of received dose intensity. J Clin Oncol 8:1935-1937, 1990
12. Veerman G, Ruiz van Haperen VWT, Vermorken JB, Noordhuis P, Braakhuis BJM, Pinedo HM, Peters GJ: Antitumor activity of prolonged as compared with bolus administration of 2′,2′-difiuorodeoxycytidine in vivo against murine colon tumors. Cancer Chemother Pharmacol 4:335-342, 1996